Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Real‑world matched comparison of talquetamab versus teclistamab in Relapsed/Refractory multiple myeloma

View Full Paper
Ask AI
Bookmark
Share

Authors

MFMohammad FaizanZKZainab Zaib KhanAHAli Shan Hafeez

Discussion

Loading...

Member takes

Overview

Matched analysis shows similar outcomes of talquetamab and teclistamab in RRMM, indicating comparable safety profiles.

Key Points

  • This research compares the effectiveness and safety of talquetamab versus teclistamab in treating relapsed/refractory multiple myeloma.
  • Used real-world data from US patients with RRMM receiving either drug.
  • Conducted 1:1 propensity-score matching to balance characteristics between cohorts.
  • Measured outcomes over a follow-up period from day +1 to +365.
  • No significant difference in 1-year mortality rates between talquetamab (17.7%) and teclistamab (21.2%).
  • Cytokine release syndrome was observed in 21.2% of talquetamab patients compared to 13.9% in teclistamab.
  • Higher rates of grade ≥3 neutropenia were noted with talquetamab (26.8%) compared to teclistamab (19.2%).
  • Talquetamab showed a lower incidence of serious infections, though early-onset neutropenia was more common.

Cite This Study

Faizan et al. (2025) studied this question.

synapsesocial.com/papers/69362f6e4fa91c937236e086https://doi.org/10.1182/blood-2025-7577
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Comparative real-world outcomes with talquetamab and teclistamab in relapsed/refractory multiple myeloma: A TriNetX observational study.2026
  2. 2Real-world comparison of anti-GPRC5D bispecific therapy versus anti-BCMA treatment in relapsed/refractory multiple myeloma after prior BCMA-directed therapy.2026
  3. 3Real‐World Evaluation of Talquetamab for the Treatment of Relapsed/Refractory Multiple Myeloma ( RRMM ): An International Myeloma Working Group Immunotherapy Registry Real‐World Analysis2026 · 2 citations
  4. 4P37 | ANALYSIS OF PATIENTS WITH PRIOR BCMA-TARGETED THERAPY AND THOSE ACHIEVING COMPLETE RESPONSE IN REALiTAL: A MULTI-COUNTRY OBSERVATIONAL STUDY OF TALQUETAMAB IN RELAPSED/REFRACTORY MULTIPLE MYELOMA OUTSIDE OF CLINICAL TRIALS2026
  5. 5Comparison of talquetamab vs teclistamab in relapsed refractory multiple myeloma.2026